Completed PHASE3 INTERVENTIONAL 2-arm NCT03675139

MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

Sponsor: Xiaojun Chen

Conditions Endometrial Hyperplasia Without Atypia

Interventions Dydrogesterone 10 MG Medroxyprogesterone Acetate

Updated 11 times since 2018 Last updated: Feb 15, 2023 Started: Feb 26, 2019 Primary completion: May 14, 2022 Completion: May 15, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Endometrial Hyperplasia Without Atypia, this trial is completed. The trial is conducted by Xiaojun Chen and has accumulated 11 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2023 — Jul 2024 [monthly]

Completed PHASE3

Status: Recruiting → Completed · Phase: PHASE2_PHASE3 → PHASE3
Jul 2022 — Mar 2023 [monthly]

Recruiting PHASE2_PHASE3
May 2022 — Jul 2022 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 6 earlier versions

Apr 2022 — May 2022 [monthly]

Recruiting PHASE2_PHASE3
Sep 2021 — Apr 2022 [monthly]

Recruiting PHASE2_PHASE3
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE2_PHASE3
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE2_PHASE3
Feb 2020 — Sep 2020 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting
Oct 2018 — Feb 2020 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xiaojun Chen

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China